Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 10:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 8,145 matching trials from the live ClinicalTrials.gov search.
Filters: Phoenix, Arizona Clear all
Completed Phase 1 Interventional

Intravitreal LFG316 in Patients With Advanced Age-related Macular Degeneration

NCT01255462
View directory record Official record
Conditions
Advanced Age-related Macular Degeneration
Interventions
LFG316
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
55 Years to 90 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
8
States / cities
Phoenix, Arizona • Beverly Hills, California • Fort Myers, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 1, 2012 · Synced Oct 19, 2026, 10:38 AM EDT
Recruiting Phase 2Phase 3 Interventional

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

NCT05987241
View directory record Official record
Conditions
Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma, Muscle Invasive Ureter Urothelial Carcinoma, Muscle Invasive Urethral Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma AJCC v6 and v7, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage IV Bladder Urothelial Carcinoma AJCC v7
Interventions
Biospecimen Collection, cfDNA or ctDNA Measurement, Computed Tomography, Cystoscopy, Magnetic Resonance Imaging, Nivolumab, Questionnaire Administration, Relatlimab
Procedure · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
992 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
492
States / cities
Phoenix, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 372 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 19, 2026, 10:38 AM EDT
Active, not recruiting No phase listed Observational

NCI COVID-19 in Cancer Patients, NCCAPS Study

NCT04387656
View directory record Official record
Conditions
COVID-19 Infection, Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Data Collection, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
1,877 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
928
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 589 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 19, 2026, 10:38 AM EDT
Completed Phase 2 Interventional Results available

Trial of Anakinra (Plus Zinc) or Prednisone in Patients With Severe Alcoholic Hepatitis

NCT04072822
View directory record Official record
Conditions
Alcoholic Hepatitis
Interventions
Anakinra and Zinc, Prednisone, Placebos
Drug
Lead sponsor
Indiana University
Other
Eligibility
21 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
10
States / cities
Phoenix, Arizona • Jacksonville, Florida • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 19, 2026, 10:38 AM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures

NCT03288129
View directory record Official record
Conditions
Partial Onset Seizures, Secondarily Generalized Seizures, Primary Generalized Tonic-Clonic Seizures
Interventions
Perampanel
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
4 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
24
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 20 more
Source: ClinicalTrials.gov public record
Updated May 16, 2022 · Synced Oct 19, 2026, 10:38 AM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety, and Tolerability of JNJ-27018966 (Eluxadoline) in the Treatment of Irritable Bowel Syndrome With Diarrhea

NCT01130272
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Eluxadoline, Placebo
Drug
Lead sponsor
Furiex Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
807 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
288
States / cities
Anniston, Alabama • Birmingham, Alabama • Dothan, Alabama + 225 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced Oct 19, 2026, 10:38 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Episodic Cluster Headache (ECH)

NCT02945046
View directory record Official record
Conditions
Episodic Cluster Headache
Interventions
Fremanezumab, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
31
States / cities
Phoenix, Arizona • Canoga Park, California • Santa Monica, California + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 19, 2026, 10:38 AM EDT
Completed Phase 3 Interventional Results available

Pivotal Trial of Dermagraft(R) to Treat Venous Leg Ulcers

NCT00909870
View directory record Official record
Conditions
Venous Leg Ulcer
Interventions
Dermagraft(R), Profore
Device
Lead sponsor
Organogenesis
Industry
Eligibility
18 Years and older
Enrollment
537 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
34
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Oct 19, 2026, 10:38 AM EDT
Completed Phase 2 Interventional

Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma

NCT00006102
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Lymphoma, Neuroblastoma, Retinoblastoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
becatecarin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
198
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 149 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2013 · Synced Oct 19, 2026, 10:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Transseptal vs Retrograde Aortic Ventricular Entry to Reduce Systemic Emboli

NCT03946072
View directory record Official record
Conditions
Neurocognitive Dysfunction
Interventions
Transseptal Aortic Approach Catheter Ablation Procedure, Retrograde Aortic Approach Catheter Ablation Procedure
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
20
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Oct 19, 2026, 10:38 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Adherence With Continuous-dose Oral Contraceptive: Evaluation of Self-Selection and Use

NCT04112095
View directory record Official record
Conditions
Contraception
Interventions
Norgestrel 0.075 mg tablets
Drug
Lead sponsor
HRA Pharma
Industry
Eligibility
11 Years and older · Female only
Enrollment
962 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
38
States / cities
Birmingham, Alabama • Homewood, Alabama • Mesa, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated May 20, 2022 · Synced Oct 19, 2026, 10:38 AM EDT
Terminated Phase 3 Interventional

Bioequivalence of Two Ciprofloxacin 0.3%/Dexamethasone 0.1% Sterile Otic Suspensions in Otitis Media in Children With Tympanostomy Tubes

NCT01994642
View directory record Official record
Conditions
Otitis Media in Patients With Tympanostomy Tubes
Interventions
Ciprofloxacin 0.3%/dexamethasone 0.1% sterile otic suspension, CIPRODEX® (ciprofloxacin 0.3%/dexamethasone 0.1%), Placebo Sterile Otic Suspension
Drug
Lead sponsor
Par Pharmaceutical, Inc.
Industry
Eligibility
6 Months to 12 Years
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
23
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2017 · Synced Oct 19, 2026, 10:38 AM EDT
Completed No phase listed Observational

AAV Gene Therapy Screening/Observational Protocol (ECLIPSE)

NCT04272554
View directory record Official record
Conditions
Hemophilia B, Blood Coagulation Disorders, Inherited, Blood Coagulation Disorder, Haematologic Disease
Interventions
Not listed
Lead sponsor
Spur Therapeutics
Industry
Eligibility
16 Years and older · Male only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
17
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2022 · Synced Oct 19, 2026, 10:38 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of ART-123 in Subjects With Sepsis and Disseminated Intravascular Coagulation

NCT00487656
View directory record Official record
Conditions
Sepsis, Disseminated Intravascular Coagulation
Interventions
ART-123, placebo
Drug
Lead sponsor
Artisan Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
49
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tuscon, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated May 18, 2011 · Synced Oct 19, 2026, 10:38 AM EDT
Completed Phase 2 Interventional

S0027: Vinorelbine Followed by Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer

NCT00026156
View directory record Official record
Conditions
Lung Cancer
Interventions
docetaxel, vinorelbine tartrate
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
96
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2013 · Synced Oct 19, 2026, 10:38 AM EDT
Completed Phase 1 Interventional Results available

Coenzyme Q10 in Relieving Treatment-Related Fatigue in Women With Breast Cancer

NCT00096356
View directory record Official record
Conditions
Breast Cancer, Fatigue
Interventions
CoQ10 & Vitamin E, Placebo & Vitamin E
Dietary Supplement
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
31
States / cities
Phoenix, Arizona • Santa Rosa, California • Newark, Delaware + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2021 · Synced Oct 19, 2026, 10:38 AM EDT
Completed Phase 2Phase 3 Interventional

Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stents to Treat De Novo Coronary Lesions

NCT00301522
View directory record Official record
Conditions
Coronary Stenosis
Interventions
TAXUS Paclitaxel-Eluting Coronary Stent, Slow-Formulation, Express2
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
72
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 58 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2010 · Synced Oct 19, 2026, 10:38 AM EDT
Completed Phase 2 Interventional Results available

Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer

NCT01267253
View directory record Official record
Conditions
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Persistent Disease, Recurrent Cervical Carcinoma
Interventions
Brivanib Alaninate, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
43
States / cities
Phoenix, Arizona • Burbank, California • San Francisco, California + 37 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Oct 19, 2026, 10:38 AM EDT
Recruiting Phase 2Phase 3 Interventional

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

NCT06989437
View directory record Official record
Conditions
Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma
Interventions
ponsegromab, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
982 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
91
States / cities
Birmingham, Alabama • Phoenix, Arizona • Bryant, Arkansas + 48 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 19, 2026, 10:38 AM EDT
Terminated Not applicable Interventional Results available

Restoration® Anatomic Dual Mobility (ADM) X3® Acetabular System Study

NCT01420237
View directory record Official record
Conditions
Arthroplasty, Replacement, Hip
Interventions
Restoration ADM X3 Device
Device
Lead sponsor
Stryker Orthopaedics
Industry
Eligibility
18 Years to 75 Years
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
9
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Oct 19, 2026, 10:38 AM EDT
Completed No phase listed Observational Results available

Correlation of Trust and Outcomes Following Physical Therapy for Chronic Low Back Pain

NCT03443401
View directory record Official record
Conditions
Trust, Chronic Low Back Pain, Physical Therapy
Interventions
Standard physical therapy care
Procedure
Lead sponsor
University of South Dakota
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
11
States / cities
Casa Grande, Arizona • Phoenix, Arizona • Chico, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 19, 2026, 10:38 AM EDT
Completed Phase 3 Interventional Results available

Maribavir Versus Oral Ganciclovir For The Prevention of Cytomegalovirus (CMV) Disease in Liver Transplant Recipients

NCT00497796
View directory record Official record
Conditions
Cytomegalovirus Infections
Interventions
maribavir, ganciclovir
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
55
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 19, 2026, 10:38 AM EDT
Completed Not applicable Interventional

Study About Group and Phone Follow-Up After a Crisis

NCT05637203
View directory record Official record
Conditions
Suicide, Crisis; Emotional
Interventions
THRIVE (Toward Hope, Recovery, Interpersonal Growth, Values, and Engagement), Discharge / Safety Planning
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Phoenix, Arizona • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 19, 2026, 10:38 AM EDT
Completed Phase 3 Interventional

Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson's

NCT00363727
View directory record Official record
Conditions
Parkinson's Disease, Parkinson Disease, Dyskinesias
Interventions
ropinirole controlled-release (REQUIP CR) for RLS
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 70 Years
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
69
States / cities
Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Oct 19, 2026, 10:38 AM EDT